[go: up one dir, main page]
Jump to content

Matthias Tschöp

Edit links
From Wikipedia, the free encyclopedia

Matthias Tschöp
Born (1967-04-07) 7 April 1967 (age 57)
Munich, Germany
EducationLudwig Maximilian University of Munich
Known forDiscovery of highly effective drugs for obesity and diabetes
Awards
Scientific career
FieldsDiabetes and obesity, drug discovery
InstitutionsHelmholtz Zentrum München; Technical University of Munich

Matthias H. Tschöp (born 7 April 1967) is a German physician and scientist. He is the chief executive officer and scientific director of Helmholtz Zentrum München, German Research Center for Environmental Health. He is also Alexander von Humboldt Professor[1] and chair of metabolic diseases at Technical University of Munich and serves as an adjunct professor at Yale University.

Career and research

[edit]

Tschöp obtained an M.D. from the Ludwig Maximilian University of Munich (1993), where he worked as a clinician (1994–1998) in neuroendocrinology before accepting a research fellowship at the Eli Lilly Discovery Research Laboratories (1999–2002) and leading a research team at the German Institute of Human Nutrition (Potsdam/Nuthetal 2002–2003). He served as a Professor of Endocrinology and Diabetes at the Metabolic Diseases Institute of the University of Cincinnati (2003–2009), before being named the Arthur Russell Morgan Endowed Chair of Medicine, and Research Director of the Metabolism Center of Excellence for Diabetes and Obesity at the University of Cincinnati (2009–2011).[2] He was Research Director of the Helmholtz Diabetes Center and Director of the Institute for Diabetes and Obesity at Helmholtz Zentrum München (2011–2018).

Early in his career, Tschöp reported on the orexigenic, adipogenic, and metabolic effects of ghrelin and its secretory control by nutrients, which has had a major influence on human obesity and diabetes research. His corresponding publication in Nature is among today's most frequently cited metabolism research papers.[3] It added a fundamental pathway to the current model of body weight and glucose control and established novel drug targets for metabolic diseases. Tschöp went on to further dissect gut-brain communication pathways, based on GI-hormone signaling and lessons from unraveling the molecular underpinnings of gastric bypass surgery.

Together with his close collaborator Richard DiMarchi (Indiana University)[4] he discovered and validated the novel drug class of dual and triple gut hormone co-agonists for the treatment of obesity and diabetes. These new drugs simultaneously target several receptors and reduce body weight and blood sugar with unprecedented efficacy. Several of these compounds are in clinical trials for the treatment of diabetes and obesity and one representative of this drug class, the GIP/GLP1 receptor dual agonist Tirzepatide (Mounjaro, Eli Lilly and Company) was FDA approved for diabetes in 2022. Tschöp and DiMarchi more recently went on to discover and validate another class of drug candidates by engineering peptide to deliver steroid/small molecules to selected cell populations.[5]

In 2022, Tschöp was a candidate to succeed Heinz Engl as rector of the University of Vienna; however, he ultimately withdrew his application.[6] As of January 2023, he is the vice president for health of the Helmholtz Association of German Research Centers.[7]

Other activities

[edit]
  • Cell, Member of the Advisory Board (since 2020)[8]
  • Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Member of the Scientific Advisory Board[9]

Awards and recognition

[edit]

References

[edit]
  1. ^ Award winners 2012: Prof. Dr. Matthias Tschöp. humboldt-professur.de. Retrieved 15 January 2014.
  2. ^ American Society for Clinical Investigation (ASCI). the-asci.org. Retrieved 22 January 2015.
  3. ^ Tschöp, Matthias; Smiley, David L.; Heiman, Mark L. (2000). "Ghrelin induces adiposity in rodents". Nature. 407 (6806): 908–913. Bibcode:2000Natur.407..908T. doi:10.1038/35038090. PMID 11057670. S2CID 4564644.
  4. ^ Claiborn, Kathryn (2011). "Masters of metabolism: Matthias Tschöp and Richard di Marchi". Journal of Clinical Investigation. 121 (8): 2952. doi:10.1172/JCI59886. PMC 3148758.
  5. ^ Gruber, Karl (2015). "Moving towards a more precise treatment of diabetes". The Lancet Diabetes & Endocrinology. 3 (3): 171. doi:10.1016/S2213-8587(15)00010-8. PMID 25702247.
  6. ^ Rektorensuche an der Uni Wien: Einziger internationaler Kandidat hat abgesagt Der Standard, 21 March 2022.
  7. ^ Matthias Tschöp New Vice President of the Helmholtz Association. Retrieved 12 April 2023.
  8. ^ Advisory Board 'Cell.
  9. ^ Scientific Advisory Board Institute of Metabolism and Systems Research (IMSR), University of Birmingham.
  10. ^ Six new honorary doctorates at Stockholm University 2024. Retrieved 29 April 2024
  11. ^ Professor Dr Dr h.c. Matthias H. Tschöp, Heinrich Wieland Laureate 2023. Retrieved 27 October 2023.
  12. ^ Fight against Obesity and Diabetes: Matthias Tschöp receives Ernst Schering Prize 2023. Retrieved 17 August 2023.
  13. ^ Extraordinary Leaders in Diabetes Research, Prevention, and Treatment to be Recognized at the ADA's 83rd Scientific Sessions. Retrieved 24 March 2023.
  14. ^ EASD Annual Meeting: Numerous Prizes for DZD Researchers. Retrieved 24 September 2022.
  15. ^ Matthias Tschoep receives the highest honor from the German Diabetes Association. www.dzd-ev.de/en. Retrieved 7 June 2019.
  16. ^ Matthias Tschöp receives Bavarian honor. tum.de. Retrieved 4 November 2019.
  17. ^ DZD Scientist Matthias Tschöp to Receive Carus Medal. dzd-ev.de. Retrieved 7 November 2019.
  18. ^ Charles H. Best Lectureship and Award. physiology.utoronto.ca. Retrieved 25 December 2017.
  19. ^ "Prestigious award from the Bayer Science & Education Foundation: 2017 Hansen Family Award goes to Professor Jens Brüning and Professor Matthias H. Tschöp". Archived from the original on 6 June 2017. Retrieved 25 December 2017.
  20. ^ Daniel J. Drucker, MD (Jan 2017). Meet the 2017 Laureates: Matthias Tschöp, MD. endocrinenews.endocrine.org. Retrieved 25 December 2017.
  21. ^ Erwin Schrödinger Preis goes to Helmholtz Zentrum München. Archived 9 February 2015 at the Wayback Machine helmholtz-muenchen.de. Retrieved 15 January 2015.
  22. ^ Moore, Charles (10 December 2014). 'Unparalleled' Results In Animal Trials Treatment To Cure Adult-onset Diabetes, Obesity. diabetesnewsjournal.com. Retrieved 15 February 2015.
  23. ^ Paul Martini Prize: Award for new approaches in the treatment of diabetes and obesity. Archived 4 March 2016 at the Wayback Machine paul-martini-stiftung.de. Retrieved 14 January 2015.
  24. ^ Gill Symposium honors two neuroscientists for work on the brain's role in regulating metabolism. archive.news.indiana.edu. Retrieved 7 November 2019.
  25. ^ Prof. Dr. Matthias Tschöp. leopoldina.org. Retrieved 14 January 2015.
  26. ^ "American Diabetes Association Honors UC Researcher With Scientific Achievement Award". Archived from the original on 6 January 2018. Retrieved 5 January 2018.
  27. ^ "Tschöp to Receive NIDDK Scholar Award". Archived from the original on 6 January 2018. Retrieved 5 January 2018.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Matthias_Tschöp&oldid=1257555054"